clinical trial · NCT06285825
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
M.D. Anderson Cancer Center·phase2·recruiting·n = 32
CytopeniaEmapalumab
brief summary
To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
started
Jul 5, 2024
primary completion
Aug 22, 2026
completion
Aug 22, 2028
last updated
Feb 11, 2026
detailed description
Primary Objectives:
\- To evaluate the efficacy of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Secondary Objectives:
\- To evaluate safety and tolerability of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Exploratory Objective:
\- To investigate biomarkers of response and resistance to emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol